🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks.Unlock full list

More Than $4M Bet On Better Therapeutics? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying

Published 13/04/2023, 14:19
© Reuters.  More Than $4M Bet On Better Therapeutics? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying
NNBR
-
NNGRY
-
BTTX
-

Benzinga - The Dow Jones closed lower by around 38 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

Better Therapeutics

  • The Trade: Better Therapeutics, Inc. (NASDAQ: BTTR) 10% owner David P. Perry 2015 Trust acquired a total 4,969,697 shares an average price of $0.82. To acquire these shares, it cost around $4.1 million. The company’s other Directors also purchased the company’s shares.
  • What’s Happening: Better Choice Company reported worse-than-expected Q4 sales results.
  • What Better Therapeutics Does: Better Therapeutics Inc is a prescription digital therapeutics company developing a novel form of cognitive behavioural therapy to address the root causes of cardiometabolic diseases.
NN
  • The Trade: NN, Inc. (NASDAQ: NNBR) 10% owner Hjalmar Eric Soderlund acquired a total of 171,325 shares at an average price of $1.06. The insider spent around $182.11 thousand to buy those shares.
  • What’s Happening: NN recently posted weaker-than-expected quarterly results.
  • What NN Does: NN Inc is a diversified industrial company that combines engineering and production capabilities with in-depth materials science expertise to design and manufacture high-precision solutions and components.
Check This Out: Investor Optimism Improves Slightly Following Inflation Data

Heliogen

  • The Trade: Heliogen, Inc. (NYSE: HLGN) 10% owner Patrick Soonshiong acquired a total of 540,650 shares at an average price of $0.25. To acquire these shares, it cost around $135.04 thousand.
  • What’s Happening: Heliogen recently posted a wider-than-expected quarterly loss.
  • What Heliogen Does: Heliogen Inc is a concentrated solar energy system that is being developed to unlock the power of sunlight to replace fossil fuels.
Don’t forget to check out our premarket coverage here

Vicarious Surgical

  • The Trade: Vicarious Surgical Inc. (NYSE: RBOT) Director Philip Liang acquired a total of 17,002 shares at an average price of $2.26. The insider spent $38.41 thousand to buy those shares.
  • What’s Happening: Vicarious Surgical, during February, posted a narrower-than-expected quarterly loss.
  • What Vicarious Surgical Does: Vicarious Surgical Inc designs a surgical robot that enables surgeons to perform minimally invasive surgery with 3D visualization and accurate control.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.